The FDA granted accelerated approval to Ascendis Pharma’s once‑weekly TransCon CNP (now branded Yuviwel; navepegritide) for children aged two and older with achondroplasia. The clearance, based on improvements in annualized growth velocity (AGV), ends BioMarin’s de facto monopoly in the indication and awards Ascendis a rare pediatric disease priority review voucher. Ascendis must confirm clinical benefit in post‑marketing studies to retain approval. The company expects to make Yuviwel available via prescribing physicians in Q2, but has not yet announced pricing. Analysts project modest 2026 uptake with larger contributions possible in 2027 and beyond as additional approvals or label expansions materialize. Market analysts and clinicians noted the approval intensifies competition with BioMarin’s daily Voxzogo shot and could prompt switching among patients seeking a weekly regimen. Ascendis said the approval represents a notable regulatory win amid uncertainty around FDA timelines for novel pediatric therapies.